共 98 条
[1]
Vaughn C(2018)An update on the use of disease-modifying therapy in pregnant patients with multiple sclerosis CNS Drugs 32 161-178
[2]
Bushra A(2018)ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis Eur J Neurol 25 215-237
[3]
Kolb C(2018)ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis Mult Scler 24 96-120
[4]
Weinstock-Guttman B(2019)UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines Pract Neurol 79 1130-1135
[5]
Montalban X(2012)Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review Neurology 22 801-809
[6]
Gold R(2016)Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry Mult Scler 255 1250-1253
[7]
Thompson AJ(2008)Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? J Neurol 75 1794-1802
[8]
Otero-Romero S(2010)Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis Neurology 2016 1034912-534
[9]
Amato MP(2016)Pregnancy and the use of disease-modifying therapies in patients with multiple sclerosis: benefits versus risks Mult Scler Int 16 523-253
[10]
Chandraratna D(2017)Treatment of multiple sclerosis during pregnancy—safety considerations Expert Opin Drug Saf 4 e004536-589